X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11784) 11784
Newsletter (340) 340
Newspaper Article (100) 100
Magazine Article (87) 87
Book Chapter (27) 27
Dissertation (16) 16
Publication (6) 6
Conference Proceeding (5) 5
Web Resource (4) 4
Book Review (3) 3
Streaming Video (2) 2
Transcript (2) 2
Paper (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
metformin (9126) 9126
humans (7521) 7521
female (4639) 4639
male (4355) 4355
diabetes mellitus, type 2 - drug therapy (3969) 3969
diabetes (3603) 3603
type 2 diabetes (3412) 3412
hypoglycemic agents - therapeutic use (3354) 3354
endocrinology & metabolism (3068) 3068
metformin - therapeutic use (2991) 2991
middle aged (2973) 2973
hypoglycemic agents - administration & dosage (2602) 2602
metformin - administration & dosage (2492) 2492
adult (2413) 2413
insulin (2407) 2407
animals (2213) 2213
glucose (2192) 2192
aged (2103) 2103
pharmacology & pharmacy (1877) 1877
diabetes mellitus (1841) 1841
research (1683) 1683
drug therapy (1678) 1678
dosage and administration (1608) 1608
treatment outcome (1599) 1599
insulin resistance (1588) 1588
drug therapy, combination (1583) 1583
hypoglycemic agents - adverse effects (1500) 1500
care and treatment (1496) 1496
metformin - pharmacology (1493) 1493
diabetes therapy (1488) 1488
diabetes mellitus, type 2 - blood (1397) 1397
glycemic control (1301) 1301
risk factors (1223) 1223
analysis (1218) 1218
blood glucose - metabolism (1194) 1194
hypoglycemic agents (1191) 1191
double-blind (1185) 1185
hypoglycemic agents - pharmacology (1171) 1171
therapy (1155) 1155
health aspects (1055) 1055
mellitus (1055) 1055
metformin - adverse effects (1013) 1013
obesity (1004) 1004
metabolism (977) 977
risk (977) 977
medicine, general & internal (972) 972
blood glucose - drug effects (966) 966
mice (957) 957
insulin-resistance (943) 943
rats (941) 941
hyperglycemia (896) 896
internal medicine (894) 894
clinical trials (855) 855
efficacy (855) 855
cancer (811) 811
administration, oral (794) 794
double-blind method (782) 782
glycated hemoglobin a - metabolism (777) 777
safety (767) 767
medicine & public health (765) 765
dextrose (756) 756
endocrine system diseases (709) 709
mortality (700) 700
body mass index (680) 680
oncology (677) 677
complications and side effects (675) 675
diabetes mellitus, type 2 - complications (674) 674
activated protein-kinase (668) 668
studies (664) 664
hypoglycemia (661) 661
insulin - therapeutic use (650) 650
type 2 diabetes mellitus (639) 639
adolescent (638) 638
pharmacokinetics (630) 630
nutritional and metabolic diseases (625) 625
patients (624) 624
kinases (623) 623
dose-response relationship, drug (621) 621
management (607) 607
young adult (606) 606
women (590) 590
medicine, research & experimental (587) 587
drug administration schedule (585) 585
abridged index medicus (580) 580
drugs (576) 576
medicine (572) 572
oxidative stress (570) 570
pregnancy (568) 568
polycystic ovary syndrome - drug therapy (559) 559
physiological aspects (556) 556
body weight (552) 552
diabetes mellitus, type 2 - metabolism (549) 549
insulin - blood (537) 537
proteins (532) 532
medical research (530) 530
rodents (529) 529
glycated hemoglobin a - analysis (527) 527
prevention (524) 524
blood glucose - analysis (521) 521
insulin - administration & dosage (520) 520
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11972) 11972
German (112) 112
French (67) 67
Spanish (57) 57
Japanese (55) 55
Chinese (38) 38
Russian (33) 33
Italian (16) 16
Portuguese (14) 14
Polish (13) 13
Swedish (12) 12
Korean (9) 9
Hungarian (8) 8
Czech (7) 7
Danish (5) 5
Norwegian (5) 5
Persian (5) 5
Dutch (4) 4
Bulgarian (3) 3
Serbian (3) 3
Turkish (3) 3
Indonesian (2) 2
Ukrainian (2) 2
Hebrew (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9739, pp. 431 - 439
Journal Article
Diabetes care, ISSN 1935-5548, 2014, Volume 37, Issue 8, pp. 2317 - 2325
Journal Article
Diabetes care, ISSN 1935-5548, 2011, Volume 35, Issue 2, pp. 252 - 258
Journal Article
Diabetes care, ISSN 1935-5548, 2014, Volume 37, Issue 8, pp. 2149 - 2158
Journal Article
Diabetes care, ISSN 1935-5548, 2013, Volume 36, Issue 8, pp. 2254 - 2261
Journal Article
Diabetes care, ISSN 1935-5548, 2017, Volume 40, Issue 4, pp. 468 - 475
Journal Article
Journal Article
Diabetologia, ISSN 1432-0428, 2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2014, Volume 16, Issue 5, pp. 467 - 477
Aim The efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM)... 
thiazolidinediones | metformin | type 2 diabetes | phase 3 study | SGLT2 inhibitor | Type 2 diabetes | Metformin | Phase 3 study | Thiazolidinediones | GLYCEMIC CONTROL | PLACEBO | ADD-ON | SULFONYLUREA | MONOTHERAPY | SITAGLIPTIN | BODY-WEIGHT | ENDOCRINOLOGY & METABOLISM | COTRANSPORTER 2 INHIBITOR | PANCREATIC-FUNCTION | Thiophenes - therapeutic use | Triazoles - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Pyrazines - administration & dosage | Lipids | Male | Thiophenes - administration & dosage | Genital Diseases, Female - chemically induced | Thiazolidinediones - administration & dosage | Hypoglycemic Agents - administration & dosage | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Candidiasis - chemically induced | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Diuretics, Osmotic - adverse effects | Double-Blind Method | Genital Diseases, Male - chemically induced | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucose metabolism | Care and treatment | Analysis | Low density lipoproteins | Hemoglobin | Glucose | Dextrose | Drug therapy | Diabetes | Original
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 09/2017, Volume 262, pp. 296 - 304
In this work, a fixed-dose combination of gabapentin and flurbiprofen formulated as multilayer tablets has been designed, developed and studied in vitro and in... 
Gabapentin | Multilayer tablets | Fixed-dose combination | Human in vivo studies | Flurbiprofen | METFORMIN | MONOTHERAPY | DELIVERY SYSTEMS | CHEMISTRY, MULTIDISCIPLINARY | ADHERENCE | TABLETS | THERAPY | DRUGS | PHARMACOLOGY & PHARMACY | ABSORPTION | SUSTAINED-RELEASE | Polymers - administration & dosage | Tablets | GABA Agonists - administration & dosage | Humans | Middle Aged | Male | gamma-Aminobutyric Acid - administration & dosage | Analgesics - pharmacokinetics | Intestines - metabolism | Stomach - metabolism | Delayed-Action Preparations - administration & dosage | Young Adult | Flurbiprofen - administration & dosage | Delayed-Action Preparations - pharmacokinetics | Amines - administration & dosage | Adult | Female | gamma-Aminobutyric Acid - pharmacokinetics | Flurbiprofen - pharmacokinetics | GABA Agonists - pharmacokinetics | Administration, Oral | Food-Drug Interactions | Analgesics - administration & dosage | Cyclohexanecarboxylic Acids - administration & dosage | Cross-Over Studies | Adolescent | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Polymers - pharmacokinetics | Amines - pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Drug Liberation | Cyclohexanecarboxylic Acids - pharmacokinetics | Drug Combinations | Dosage and administration | Drug therapy, Combination | Polymers
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 3, pp. 302.e1 - 302.e7
Abstract Objective Six oral medication classes have been approved by the Food and Drug Administration for the treatment of type 2 diabetes... 
Internal Medicine | Pharmacotherapy | Diabetes | Cost-effectiveness | Quality of care | STATEMENT | EUROPEAN-ASSOCIATION | MANAGEMENT | MYOCARDIAL-INFARCTION | RISK | ADJUSTMENT | MEDICINE, GENERAL & INTERNAL | HYPERGLYCEMIA | THERAPY | CONSENSUS ALGORITHM | ROSIGLITAZONE | Metformin - therapeutic use | Hypoglycemic Agents - economics | United States | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Thiazolidinediones - administration & dosage | Sulfonylurea Compounds - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Metformin - economics | Practice Patterns, Physicians' - statistics & numerical data | Thiazolidinediones - therapeutic use | alpha-Glucosidases - therapeutic use | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | alpha-Glucosidases - economics | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Hypoglycemic Agents - therapeutic use | Administration, Oral | Sulfonylurea Compounds - therapeutic use | Logistic Models | Thiazolidinediones - economics | Evidence-Based Medicine | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | alpha-Glucosidases - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Quality of Health Care | Type 2 diabetes | Prices and rates | Hypoglycemic agents | Dosage and administration | Research | Drug therapy | Medical care, Cost of | Diabetes therapy
Journal Article